TESARO

TESARO, Inc.
Investor Relations Department
1000 Winter St., Ste. 3300
Waltham, MA 02451
United States

Visit IR website
Sign-up for Email alerts

NASDAQ: TSRO	
Last Trade:	147.59
Trade Time:	4:00 PM ET 4/28/2017
Change:	0.98 (+0.668%)
Day Range	143.57 - 148.51
52-Week Range	36.68 - 192.94
Volume	596,630

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Founded in 2010, TESARO is a publicly-traded oncology focused company dedicated to improving the lives of cancer patients. The Company intends to leverage the experience and competencies of its management team to identify, acquire and develop promising drug candidates. Upon successful development and regulatory approval of any of our product candidates, TESARO intends to make them available to cancer patients in North America, Europe and China through its own commercialization efforts and to establish a network of licensees and distributors in other geographic areas. For more information... (more)

Stock Performance



Press Releases [View all]

4/27/2017
TESARO Initiates Registrational Development Program for Anti-PD-1 Antibody TSR-042

4/26/2017
TESARO Announces Approval of VARUBY® (Oral Rolapitant Tablets) by European Commission

4/25/2017
TESARO to Announce First-Quarter 2017 Financial Results on May 9, 2017

4/25/2017
Tesaro Announces Participation in Two Investor Conferences

4/19/2017
TESARO Announces Availability of Zejula™ (Niraparib) for Patients With Recurrent Ovarian Cancer in the U.S.

Upcoming Events [View all]

5/09/2017 4:15 PM
TESARO Inc. First Quarter Financial Results

5/17/2017 3:00 PM PT
The Bank of America Merrill Lynch 2017 Healthcare Conference

Financials [View all]

2/28/2017
Annual Report (10-K)

4/07/2017
Proxy Statement (DEF 14A)

11/04/2016
Quarterly Report (10-Q)

8/05/2016
Quarterly Report (10-Q)

5/06/2016
Quarterly Report (10-Q)